It resulted in a 1.4–2.3-fold higher absorbed dose to tumor lesions (6.64 Gy/GBq) as compared with published values for [177Lu]Lu-PSMA-617 (3.87 Gy/GBq [37], 4.60 Gy/GBq [38], and 2.80 Gy/GBq [39]) and [177Lu]Lu-PSMA I&T (3.30 Gy/GBq [40] and 3.20 Gy/GBq [41]), respectively. The gene discussed is FOLH1; the disease is neoplasm.